Coronavirus in Peru | Francisco Sagasti announces signing agreement with Sinopharm and AstraZeneca to purchase COVID-19 vaccine

president Francisco Sagasti Announcing the signing of an agreement with Chinese pharmaceutical company Sinopharm for the supply of 38 million doses. Vaccine Against COVID-19 In a message to the nation, the president announced that the first million vaccines will arrive in January. Two times required

This is the first agreement the Peruvian state has signed with a pharmaceutical company for the purchase of the vaccine.

Sinopharm vaccine is 79% effective and is “Conditional” for marketing from the Chinese health agency, Sinopharm is the first Chinese pharmaceutical group to report data on the effectiveness of vaccines in their preparations.

United Arab Emirates and Egypt It is the other two countries that have announced they have approved a vaccine made by Sinopharm with the Beijing Institute of Biological Products.

The efficacy rate of Sinopharm’s vaccine is lower than what competitors Pfizer / BioNTech (95%) and Moderna claim (94.1%).

Peru is part of the Phase III clinical trial of the Sinopharm vaccine. Thousands of people volunteer and receive both of these vaccines under the supervision of the Sinopharm. Cayetano Heredia Peruvian University (UPCH) and National University of San Marcos (UNMSM)